Method for enriching ubiquitinated protein and enrichment kit
The enrichment of ubiquitinated proteins through the interaction between self-labeling proteins and ligands solves the problem of low detection specificity in the prior art, and achieves high purity and high specificity of ubiquitinated proteins, which significantly Improve the accuracy of the test results.
Patent Information
- Application Number
- CN202411079627.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is not specific and is susceptible to interference from non-ubiquitinated peptides when detecting the ubiquitination level of targeted proteins, resulting in inaccuracy of the detection results.
The ubiquitinated protein is enriched by the interaction between self-labeling protein and corresponding ligand. By constructing a recombinant plasmid of ubiquitin-TEV-self-labeling protein, the ubiquitinated protein is expressed in cells, and the corresponding combinations containing self-labeling proteins are used. The magnetic beads of the body were captured and TEV protease cleaved to achieve high purity enrichment.
It improves the specificity and purity of the detection, is suitable for strict cleaning conditions, avoids background interference, and significantly improves the purification effect of ubiquitinated protein.
Smart Images

Figure CN118978584A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a method for enriching ubiquitinated proteins and an enrichment kit. Background Art
[0002] Targeted protein degradation drugs have been a hot topic in the field of drug development in recent years. The ubiquitination-proteasome system has been widely studied as a way of endogenous protein degradation.
[0003] Ubiquitination refers to the process in which ubiquitin (a low molecular weight protein) molecules, under the action of a series of special enzymes, classify proteins in cells, select target protein molecules from them, and specifically modify the target proteins. The ubiquitination-proteasome system realizes its functions in two steps: the first step is to ubiquitinate the protein to be degraded to obtain ubiquitinated protein; the second step is that the ubiquitinated protein is further degraded by the proteasome.
[0004] In the development of the ubiquitination-proteasome system, detecting the ubiquitination level of the target protein is a critical step. Since the ubiquitination state of a specific protein lasts for a very short time, the absolute total amount of all ubiquitin-modified proteins is not high. Therefore, to detect the ubiquitination level of the target protein, it is necessary to enrich it first and then detect it.
[0005] Enrichment of ubiquitinated proteins can be divided into enrichment at the protein level or at the peptide level. At the protein level, different enrichment materials, such as commercial TUBEs, can be used to enrich ubiquitinated proteins. At the peptide level, specific K-ε-GG peptides are mainly produced after enzymatic digestion with trypsin and other enzymes, and then immunoaffinity antibodies are used for specific enrichment and purification. The immunoaffinity antibody method is a method based on antigen-antibody specific interactions, but the affinity specificity for low-abundance ubiquitinated proteins is not high. The proportion of non-ubiquitinated peptides produced after enzymatic digestion is high, which seriously interferes with the detection of ubiquitinated proteins. Summary of the invention
[0006] In view of the above-mentioned defects of the prior art, the present invention provides a method for enriching ubiquitinated proteins, which is based on the interaction between self-labeled proteins and corresponding ligands rather than antibody recognition, to achieve the enrichment of ubiquitinated proteins and improve the specificity of detection. To this end, the present invention also provides an enrichment kit.
[0007] The first aspect of the present invention provides a method for enriching ubiquitinated proteins, comprising the following steps:
[0008] S1, constructing a ubiquitin-TEV-self-marking protein recombinant plasmid carrying ubiquitin gene, TEV sequence and self-marking protein gene;
[0009] S2, mixing the plasmid carrying the gene of the protein to be enriched with the recombinant plasmid, and introducing the plasmid into the cell for expression to obtain the ubiquitinated protein;
[0010] S3, adding lysis solution and magnetic beads to capture ubiquitinated proteins, wherein the magnetic beads are magnetic beads containing corresponding ligands of self-labeled proteins;
[0011] S4. Add TEV protease and centrifuge to obtain the enriched ubiquitinated proteins.
[0012] As a preferred embodiment, the S2 includes the step of adding a transfection reagent.
[0013] As a preferred embodiment, the S2 further comprises: a protease inhibitor and a deubiquitinase inhibitor.
[0014] As a preferred embodiment, the protease inhibitor is MG132.
[0015] Protease inhibitors are reagents that prevent the degradation of ubiquitinated proteins, thereby preventing the degradation of ubiquitinated proteins from affecting the enrichment effect.
[0016] As a preferred embodiment, the deubiquitinase inhibitor is PR619.
[0017] Deubiquitinase inhibitors are agents that prevent the deubiquitination of ubiquitinated proteins.
[0018] The second aspect of the present invention provides an enrichment kit, comprising a recombinant plasmid of ubiquitin-TEV-self-marking protein, a lysate, magnetic beads and TEV protease, wherein the magnetic beads contain corresponding ligands of the self-marking protein.
[0019] As a preferred embodiment, the enrichment kit includes a transfection reagent.
[0020] As a preferred embodiment, the enrichment kit further comprises a protease inhibitor and a deubiquitinase inhibitor.
[0021] As a preferred embodiment, the protease inhibitor is MG132.
[0022] As a preferred embodiment, the deubiquitinase inhibitor is PR619.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] (1) The method for enriching ubiquitinated proteins of the present invention is based on the interaction between the self-labeled protein and the corresponding ligand to achieve the enrichment of ubiquitinated proteins instead of antibody recognition, thereby improving the specificity of detection.
[0025] (2) The method of enriching ubiquitinated proteins of the present invention is a covalent binding method, which has a higher strength than the binding of traditional antibodies and antigens and can be applied to very stringent cleaning conditions, thus facilitating the purification of ubiquitinated proteins.
[0026] (3) In the method for enriching ubiquitinated proteins of the present invention, the elution of ubiquitinated proteins is based on the cleavage of TEV protease rather than indiscriminate denaturation elution, so that the enriched ubiquitinated proteins have higher purity and avoid background interference.
[0027] The concept, specific structure and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, characteristics and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is a schematic diagram of the results of using Western blotting to detect ubiquitinated AR levels. DETAILED DESCRIPTION
[0029] In order to make the technical means, creative features, objectives and effects of the invention easier to understand, the invention is further described below with reference to specific diagrams. However, the invention is not limited to the following implementation cases.
[0030] It should be noted that the structures, proportions, sizes, etc. illustrated in the drawings in this specification are only used to match the contents disclosed in the specification so as to facilitate understanding and reading by persons familiar with this technology. They are not used to limit the conditions under which the present invention can be implemented, and therefore have no substantive technical significance. Any structural modification, change in proportion or adjustment of size, without affecting the effects and purposes that can be achieved by the present invention, should still fall within the scope of the technical contents disclosed by the present invention.
[0031] The existing method for enriching ubiquitinated proteins is mainly the immunoaffinity antibody method. This method has low affinity specificity for low-abundance ubiquitinated proteins, and the non-ubiquitinated peptides produced after enzymatic digestion account for a high proportion, which seriously interferes with the detection of ubiquitinated proteins.
[0032] In order to overcome this problem, the inventors of the present application used self-labeling protein to construct a recombinant plasmid of ubiquitin-TEV-self-labeling protein, mixed the plasmid carrying the gene of the protein to be enriched with the recombinant plasmid, introduced it into the cell for expression, obtained ubiquitinated protein, and captured the ubiquitinated protein using magnetic beads containing the corresponding ligands of the self-labeling protein to enrich the ubiquitinated protein.
[0033] Ubiquitin is a small protein present in all eukaryotic organisms. It is composed of 76 amino acids and has a molecular weight of approximately 8.451 kDa. The main function of ubiquitin is to mark proteins that need to be broken down so that they can be degraded by the proteasome.
[0034] Ubiquitinated protein is the product of target protein modified by ubiquitin. The modification of target protein by ubiquitin involves a series of reactions of ubiquitin activating enzyme E1, ubiquitin conjugating enzyme E2 and ubiquitin ligase E3: first, under the condition of ATP energy supply, enzyme E1 adheres to the Cys residue at the tail of ubiquitin molecule to activate ubiquitin, then E1 transfers the activated ubiquitin molecule to E2 enzyme, then E2 enzyme and some different types of E3 enzymes jointly recognize target protein and ubiquitinate it to obtain ubiquitinated protein.
[0035] TEV (Tobacco Etch Virus) is a plant virus belonging to Potato Virus Y. TEV protease is a highly sequence-specific cysteine protease extracted from tobacco etch virus. Due to its high sequence specificity, it is used for controlled cleavage of fusion proteins in vitro and in vivo. The TEV sequence used in this application is EDLYFQS.
[0036] Self-labeling enzyme is a protein with self-labeling function. Commonly used self-labeling proteins:
[0037] 1) Halo Tag, Halo Tag protein is a mutant of a bacterial dehalogenase that removes halogens from aliphatic hydrocarbon molecules through nucleophilic aspartic acid residues. The wild-type enzyme is able to regenerate its catalytic site to promote further dehalogenation, and the genetically engineered Halo Tag protein allows it to form an irreversible covalent bond with the substrate. This type of connection allows the protein to form a stable bond with any selected labeled chloroalkane ligand, which is very useful for downstream applications. Halo Tag is used in this application, and of course other self-labeling proteins can also be selected.
[0038] 2) SNAP-Tag, SNAP-Tag is based on human O6-alkylguanine-DNA-alkytransferase (hATG), a DNA repair enzyme that transfers the alkyl group of mutant hexaalkylguanine DNA to its cysteine residue to release guanine. Using this irreversible process, the hATG-based SNAP-Tag protein can specifically recognize and react with benzylguanine (BG).
[0039] 3) CLIP-Tag, CLIP-Tag is used to complement SNAP-Tag, and both types of fusions can be applied in one experiment. CLIP-Tag protein is also a derivative of hATG and has the same properties as SNAP-Tag protein. CLIP-Tag specifically recognizes and reacts with benzylcytosine (BC), which is a labeled cytosine.
[0040] The present application provides a method for enriching ubiquitinated proteins, comprising the following steps:
[0041] S1. Construct a ubiquitin-TEV-self-marking protein recombinant plasmid carrying a ubiquitin gene, a TEV sequence and a self-marking protein gene.
[0042] S2. The plasmid carrying the gene of the protein to be enriched is mixed with the recombinant plasmid and then introduced into the cell for expression to obtain the ubiquitinated protein.
[0043] The proteins to be enriched here refer to proteins that can be modified by ubiquitin, such as AR protein; the cells are HEK-293T cells.
[0044] AR, androgen receptor, belongs to the steroid receptor in the nuclear receptor superfamily. AR is generally composed of four domains: N-terminal transcriptional activation domain (NTD), DNA binding domain (DBD), hinge region and ligand binding domain (LBD). AR is a protein with a molecular weight of 120,000 Daltons. It is synthesized under the guidance of the gene of the human X chromosome. The monomer that binds to androgen binds to the receptor protein and a small molecule monomer that produces 9S inactivity in the cell.
[0045] S2 also includes the step of adding a transfection reagent. There is no particular limitation on the transfection reagent that can be selected. Lipofectamine 3000 is selected here.
[0046] S2 also contains protease inhibitors and deubiquitinase inhibitors.
[0047] The protease inhibitor here is MG132, purchased from MCE, #HY-13259.
[0048] The deubiquitinase inhibitor is PR619, purchased from MCE, #HY-13814. Of course, there are other options for the deubiquitinase inhibitor here, such as TCID, purchased from Lifesensors, catalog number SI9679.
[0049] The ubiquitinated proteins obtained contain self-labeled proteins, which are convenient for subsequent screening and enrichment.
[0050] S3. Add lysate and magnetic beads containing the corresponding ligands of self-labeled proteins to capture ubiquitinated proteins.
[0051] The addition of lysis buffer allows the ubiquitinated protein to exist in a free state, and the ubiquitinated protein is enriched through the binding of magnetic beads with corresponding ligands of the self-labeled protein and the self-labeled protein.
[0052] S4. Add TEV protease and centrifuge to obtain the enriched ubiquitinated proteins.
[0053] TEV protease is added to cleave the ubiquitinated proteins, and the enriched ubiquitinated proteins are purified by centrifugation.
[0054] The specific steps include:
[0055] 1. Insert the DNA sequence of ubiquitin-TEV-self-labeling protein (SLE) into the NheI / EcoRI cloning site of the pcDNA3.1 vector to construct a ubiquitin-TEV-self-labeling protein (SLE) recombinant plasmid carrying the ubiquitin gene, TEV sequence and self-labeling protein gene.
[0056] 2. 3E 6 HEK-293T cells were seeded in a 10 cm dish containing 10 mL of DMEM complete medium and incubated overnight at 37°C with 5% CO2.
[0057] 3. Replace the culture medium with 8 mL of complete DMEM medium without antibiotics.
[0058] 4. Add 600uL serum-free culture medium to 6.25ugAR plasmid (purchased from ThermoFisher) and 6.25ug ubiquitin-TEV-SLE recombinant plasmid; add 50uL Lipofectamine 3000
[0059] (ThermoFisher, #L3000008) Add 600uL of serum-free medium; mix the two to a total volume of approximately 1300μL. Mix thoroughly by pipetting or vortexing.
[0060] 5. Incubate the mixture of the above plasmid and Lipofectamine 3000 at room temperature for 15 minutes.
[0061] 6. Remove the culture dish from the incubator. The cells should be approximately 80% confluent and continue to culture in complete DMEM medium without antibiotics.
[0062] 7. Gently add the plasmid obtained in step 5 and Lipofectamine 3000 mixture to the cells and vortex to evenly disperse the mixture.
[0063] 8. Incubate the cells at 37°C, 5% CO2 for 6-8 hours, then replace the medium with DMEM complete medium.
[0064] 9. These cells were then incubated for 42 hours.
[0065] 10. Treat cells with MG132 (MCE, #HY-13259) for 6 hours.
[0066] 11. Aspirate the culture medium and wash the cells with PBS. Then add 500 μL M-PER lysis buffer (containing protease inhibitor cocktail (ThermoFisher, #78441) + 20 μM PR619 (MCE, #
[0067] HY-13814)), incubate on ice for 20 minutes to obtain lysate. The M-PER lysate here can also be purchased directly from ThermoFisher, #78501.
[0068] 12. Spin the lysate at top speed in a microcentrifuge for 5 min and transfer the supernatant to a new tube.
[0069] 13. Use the BCA kit to determine the concentration of the above lysate.
[0070] 14. Dilute the lysates 3-fold (500 μL lysate + 1000 μL wash buffer) with wash buffer (Tris-buffered saline (TBS) + 0.05% IGEPAL CA-630 (Sigma, #I8896)).
[0071] 15. Transfer 50 μL of diluted lysate to a new tube and add 12.5 μL 5x SDS-loading buffer (ThermoFisher #39000) as input sample.
[0072] 16. Add 50 μL of microbeads containing the corresponding ligand of SLE (purchased from Promega) to the remaining sample (about 450 μL) (washed 3 times in washing buffer, 1 minute each time before use) and incubate overnight at 4°C with rotation. Pipette 50 μL of supernatant into a new tube, add 12.5 μL of 5x SDS-loading buffer as the Flow-Through sample, and discard the remaining supernatant.
[0073] 17. Wash the beads 5 times with 1 mL of washing buffer to remove unbound proteins.
[0074] 18. TEV protease cleavage of ubiquitinated proteins: For each sample, add 0.5 μL TEV protease and 50 μL washing buffer to the magnetic beads and incubate with rotation at 4°C for 6 hours. The initial concentration of TEV is 1.58 mg / mL.
[0075] 19. Spin the beads in a microcentrifuge, transfer 50 μL of the supernatant to a new tube, and add 12.5 μL of 5x SDS loading buffer as the IP-TEV cleavage sample.
[0076] 20. For the separated magnetic beads containing SEL ligand, add 50 μL of washing buffer + 12.5 μL of 5xSDS-Loading buffer and heat the sample at 100°C for 10 minutes. Separate the magnetic beads magnetically and save the supernatant as the boiled magnetic beads-TEV cut sample as the pull-down sample.
[0077] Immunoblotting was used to detect ubiquitinated AR levels using AR antibodies, and actin levels were detected using actin antibodies as an internal reference. The results are shown in Figure 1 shown.
[0078] from Figure 1 It can be seen that in the Input and Flow Through samples, because the ubiquitinated protein did not undergo the enrichment process, only proteins with a molecular weight of about 100KDa could be detected, which were AR proteins; in the Pull down samples, only the samples that overexpressed AR and SLE-Ub (SLE-labeled ubiquitin protein) at the same time detected signals different from AR proteins, while the samples that only overexpressed AR had no such signal at all, and it was speculated that the signal was the ubiquitinated AR signal; because MG-132 blocked the degradation of ubiquitinated proteins, this signal increased, further proving that the signal detected in the samples that overexpressed AR and SLE-Ub at the same time was the ubiquitinated AR signal. The ubiquitinated AR signal was detected in the samples that overexpressed AR and SLE-Ub at the same time, while the samples that only overexpressed AR had no such signal at all, indicating the high specificity and extremely low background of the system.
[0079] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. A method for enriching ubiquitinated proteins, characterized in that: The steps include: S1, constructing a ubiquitin-TEV-self-marking protein recombinant plasmid carrying ubiquitin gene, TEV sequence and self-marking protein gene; S2, mixing the plasmid carrying the gene of the protein to be enriched with the recombinant plasmid, and introducing the plasmid into the cell for expression to obtain the ubiquitinated protein; S3, adding lysis solution and magnetic beads to capture ubiquitinated proteins, wherein the magnetic beads are magnetic beads containing corresponding ligands of self-labeled proteins; S4. Add TEV protease and centrifuge to obtain the enriched ubiquitinated proteins.
2. The method for enriching ubiquitinated proteins according to claim 1, characterized in that The S2 includes the step of adding a transfection reagent.
3. The method for enriching ubiquitinated proteins according to claim 1, characterized in that The S2 also contains: protease inhibitors and deubiquitinase inhibitors.
4. The method for enriching ubiquitinated proteins according to claim 3, characterized in that The protease inhibitor is MG132.
5. The method for enriching ubiquitinated proteins according to claim 3, characterized in that: The deubiquitinase inhibitor is PR619.
6. An enrichment kit, characterized in that: The invention comprises a recombinant plasmid of ubiquitin-TEV-self-marking protein, a lysate, magnetic beads and TEV protease, wherein the magnetic beads contain corresponding ligands of the self-marking protein.
7. The enrichment kit according to claim 6, characterized in that The enrichment kit includes a transfection reagent.
8. The enrichment kit according to claim 6, characterized in that The enrichment kit also includes a protease inhibitor and a deubiquitinase inhibitor.
9. The enrichment kit according to claim 6, characterized in that The protease inhibitor is MG132.
10. The enrichment kit according to claim 6, characterized in that The deubiquitinase inhibitor is PR619.
